Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.29% $0.822
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 28.07 mill |
EPS: | -0.910 |
P/E: | -0.900 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 34.15 mill |
Avg Daily Volume: | 0.147 mill |
RATING 2024-03-28 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.900 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.15x |
Company: PE -0.900 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.757 - 0.923 ( +/- 9.88%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Safier Jacob | Buy | 10 100 | Common Stock (par value $0.01) |
2024-01-31 | Safier Jacob | Buy | 5 000 | Common Stock (par value $0.01) |
2024-01-30 | Safier Jacob | Buy | 25 000 | Common Stock (par value $0.01) |
2024-01-26 | Safier Jacob | Buy | 25 000 | Common Stock (par value $0.01) |
2024-01-25 | Safier Jacob | Buy | 25 000 | Common Stock (par value $0.01) |
INSIDER POWER |
---|
100.00 |
Last 93 transactions |
Buy: 2 544 055 | Sell: 438 608 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.822 (-3.29% ) |
Volume | 0.0107 mill |
Avg. Vol. | 0.147 mill |
% of Avg. Vol | 7.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.